🔥 CYBER MONDAY SALE ENDS TONIGHT: Save 30% or more on all Examine products Save now »

Pharmacology And Safety Of Tetradecylthioacetic Acid (TTA): Phase-1 Study

Effect None
Trial Design Cohort
Trial Length 1-7 Days
Number of Subjects 18
Sex Male
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
7 days of supplementation with TTA showed no significant or consistent effects on liver enzymes, uric acid, CRP or other relevant safety parameters at doses of 200, 600, and 1000mg in otherwise healthy persons.

Total cholesterol, LDL, and triglycerides showed a nonsignificant trend to decrease while HDL and free fatty acids were not affected. Other health parameters were unaffected over the whole group.

TTA appears to be absorbed, although the bioavailability was not calculated and the rate of absorption was different between subjects. TTA is detectable in the blood following a week of supplement cessation, but not three weeks cessation.